|
|
Article: Drug provides important option for patients with advanced disease.(colorectal cancer)
- Article from:
- Cancer Weekly
- Article date:
- September 10, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 SEP 10 - (NewsRx.com & NewsRx.net) -- The approval of a new drug for advanced colorectal cancer provides an important new option for patients whose disease has defied other therapies, said the Vanderbilt-Ingram Cancer Center investigator who led a key North American study of the drug.
The U.S. Food and Drug Administration announced August 12, 2002, that it had approved oxaliplatin to treat patients whose metastatic colorectal cancer has progressed after standard chemotherapy.
The approval was based on data from a multicenter trial in the U.S. and Canada, led by Dr. Mace L. Rothenberg, which demonstrated that adding oxaliplatin to standard ...